Navigation Links
Ultragenyx Granted Orphan Designations in Europe for Two Lead Product Candidates, UX001 for HIBM and UX003 for MPS 7

NOVATO, Calif., March 28, 2012 /PRNewswire/ -- Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7 (MPS 7).  Orphan designation in the European Union provides several benefits including 10 years of market exclusivity post-authorization, fee reductions, scientific assistance for marketing authorization and access to community marketing authorization.

UX001 is an extended release formulation of sialic acid (SA-ER) intended as a substrate replacement therapy for HIBM, a severe, neuromuscular disease caused by sialic acid deficiency.  UX003 is a recombinant human beta-glucuronidase intended as an enzyme replacement therapy for the treatment of MPS 7, an extremely rare autosomal recessive lysosomal storage disorder characterized by a deficiency of the lysosomal enzyme beta-glucuronidase. 

"Ultragenyx continues to make significant progress in advancing our pipeline of potential treatments for patients affected by ultra-rare diseases," said Emil D. Kakkis, MD, PhD, Chief Executive Officer of Ultragenyx.  "I am pleased that our regulatory team was able to obtain orphan designations in both the US and the EU so promptly for both of our lead programs.  We will continue to work collaboratively with regulatory authorities as our clinical development programs move forward." 

A Phase 2 study for UX001 SA-ER in patients with HIBM is planned to begin enrollment in the second quarter of this year.  A Phase 1 study for UX003 is anticipated to begin in the first quarter of 2013.  Both UX001 and UX003 have been granted orphan designations by the FDA.

About HIBM  

HIBM is also known as GNE myopathy, distal myopathy with rimmed vacuoles (DMRV) and Nonaka disease.  HIBM is a severe, adult-onset, progressive, genetic neuromuscular disease caused by a deficiency of an enzyme in the first step of sialic acid biosynthesis needed for the modification of proteins and fats.  Patients with HIBM typically begin to have weakness and abnormal walking at 18 to 30 years of age.  Over the ensuing 10 to 20 years, many patients progressively lose significant functional ability and become wheelchair-bound.  There are no current treatments for this disease.

About MPS 7

Mucopolysaccharidosis type 7 (MPS 7), also known as Sly syndrome, is a rare genetic, metabolic disorder.  MPS 7 is caused by the deficiency of beta-glucuronidase, an enzyme required for the breakdown of the glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate.  These complex GAG carbohydrates are a critical component of many tissues. The inability to properly breakdown GAGs leads to a progressive accumulation in many tissues and multi-system disease.  There are a wide variety of clinical symptoms including enlarged organs, stiff joints, respiratory disease and cardiac complications.  There are no approved therapies for MPS 7 today.

About Ultragenyx

Ultragenyx is a privately held, developmental stage biotechnology company committed to bringing life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases, also known as orphan and ultra-orphan diseases, to market.  The company focuses on rare metabolic diseases that affect small numbers of patients, but for which the unmet medical need is high and there are no effective treatments.  Ultragenyx intends to build a sustainable pipeline of safe and effective therapies to address these underserved diseases.  Ultragenyx' lead program, UX001, is being evaluated as a potential treatment for hereditary inclusion body myopathy (HIBM), also known as GNE myopathy.  The UX001 program has been granted orphan drug designation in the US and the EU.

The company is led by an experienced management team in rare disease therapeutics.  Ultragenyx is striving toward an improved model for successful rare disease drug development which has the potential to increase efficiency while maintaining appropriate safety and efficacy standards. The company believes that it can deliver significant value to patients by building a diverse and high quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine.

For more information on Ultragenyx, please visit the company's website at




SOURCE Ultragenyx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team
2. Ultragenyx Granted Orphan Drug Designation for UX001 SA-ER for the Treatment of Hereditary Inclusion Body Myopathy (HIBM)
3. Ultragenyx Initiates Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Muscle Wasting Disease
4. Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA)
5. Oramed Pharmaceuticals Granted Australian Patent for Important Part of the Companys Core Technology in Oral Delivery of Proteins
6. Internal Fixation Systems Announces 510(k) Approval Granted by FDA for Subtalar Implants
7. Unigene Laboratories Granted US Patent for Peptide-Based Technology for Treatment of Obesity
8. FutureNet Granted Certification for Cloud-based Ambulatory EHR
9. Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union
10. BioMarCare Technologies Ltd. Granted Access to Archived Samples in the Hadassah Medical Center
11. China Medical Technologies Receives Two Patents Granted by the UKIPO and Notice of Allowance for Four Patent Applications from the USPTO
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 Research ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural Health ... Structural electronics involves electronic and/or electrical ... structures, replacing dumb structures such as vehicle bodies ...
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):